Jagannath Palepu1, Shailesh V Shrikhande2, Debanshu Bhaduri3, Rajiv C Shah4, Bhawna Sirohi5, Verushka Chhabra4, Puneet Dhar6, Regulagedda Sastry7, Sadiq Sikora8. 1. Department of Surgical Oncology, Lilavati Hospital and Research Centre, A-791, Bandra Reclamation, K C Road, Bandra West, Mumbai, 400 050, India. drjagannath@gmail.com. 2. Department of Gastrointestinal and HPB Surgery, Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai, 400 012, India. 3. Department of Surgical Oncology, M N Budhrani Cancer Institute and Research Center, Pune, 411 001, India. 4. Department of Surgical Oncology, Lilavati Hospital and Research Centre, A-791, Bandra Reclamation, K C Road, Bandra West, Mumbai, 400 050, India. 5. Department of Medical Oncology, Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai, 400 012, India. 6. Department of GI Surgery, Amrita Institute of Medical Sciences and Research, Kochi, 682 041, India. 7. Department of Surgical Gastroenterology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, 500 082, India. 8. Department of Surgical Gastroenterology, Manipal Hospital, 98, HAL Airport Road, Bengaluru, 560 017, India.
Abstract
INTRODUCTION: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors. We report data of 407 GEP-NET cases from a neuroendocrine tumor (NET) registry in India. METHODS: The AP-NET registry is an open-label, multicenter, longitudinal observational registry of patients with GEP-NETs in which six tertiary care oncology centers contributed data. Data was prospectively entered in a dedicated computerized database and was reviewed retrospectively. The patients were divided into three cohorts-those diagnosed from 2001 to 2005, from 2006 to 2010, and from 2011 to 2016. RESULTS: Of the 407 cases registered, 37 were in Cohort I, 136 in Cohort II, and 234 in Cohort III. Majority were symptomatic with only 98 patients (24.0%) asymptomatic. The most common presentation of non-functional tumors was abdominal pain (42.4%), while functional tumors presented most commonly with carcinoid syndrome. Use of DOTA-PET, introduced in 2011, has increased evaluation in 33.3% patients in Cohort III. The most common primary site was pancreas in all three cohorts. Male preponderance (58.3%) was seen. Histopathological grading was obtained in 230 (56.5%) patients-118 (29%) Grade I, 74 (18.2%) Grade II, and 36 (8.8%) Grade III NET. CONCLUSION: This report highlights changing trends in the diagnosis and reporting of NETs over the last 15 years.
INTRODUCTION:Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors. We report data of 407 GEP-NET cases from a neuroendocrine tumor (NET) registry in India. METHODS: The AP-NET registry is an open-label, multicenter, longitudinal observational registry of patients with GEP-NETs in which six tertiary care oncology centers contributed data. Data was prospectively entered in a dedicated computerized database and was reviewed retrospectively. The patients were divided into three cohorts-those diagnosed from 2001 to 2005, from 2006 to 2010, and from 2011 to 2016. RESULTS: Of the 407 cases registered, 37 were in Cohort I, 136 in Cohort II, and 234 in Cohort III. Majority were symptomatic with only 98 patients (24.0%) asymptomatic. The most common presentation of non-functional tumors was abdominal pain (42.4%), while functional tumors presented most commonly with carcinoid syndrome. Use of DOTA-PET, introduced in 2011, has increased evaluation in 33.3% patients in Cohort III. The most common primary site was pancreas in all three cohorts. Male preponderance (58.3%) was seen. Histopathological grading was obtained in 230 (56.5%) patients-118 (29%) Grade I, 74 (18.2%) Grade II, and 36 (8.8%) Grade III NET. CONCLUSION: This report highlights changing trends in the diagnosis and reporting of NETs over the last 15 years.
Entities:
Keywords:
GEP-NET; NET registry; Neuroendocrine tumors; Pancreatic NET
Authors: Ben Lawrence; Bjorn I Gustafsson; Mark Kidd; Marianne Pavel; Bernhard Svejda; Irvin M Modlin Journal: Endocrinol Metab Clin North Am Date: 2011-03 Impact factor: 4.741
Authors: R Garcia-Carbonero; J Capdevila; G Crespo-Herrero; J A Díaz-Pérez; M P Martínez Del Prado; V Alonso Orduña; I Sevilla-García; C Villabona-Artero; A Beguiristain-Gómez; M Llanos-Muñoz; M Marazuela; C Alvarez-Escola; D Castellano; E Vilar; P Jiménez-Fonseca; A Teulé; J Sastre-Valera; M Benavent-Viñuelas; A Monleon; R Salazar Journal: Ann Oncol Date: 2010-02-05 Impact factor: 32.976